Free tool
FAERS Monitor: Somatuline Depot
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022074 or its brand name (Somatuline Depot, Lanreotide Acetate). Reports on generic versions are filed under their own applications.
Reports
7,953
Serious
4,731
59% of reports
Hospitalization
1,619
Death reported
1,485
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,514
- diarrhoea1,440
- death1,278
- fatigue983
- nausea735
- injection site pain601
- abdominal pain573
- headache507
- malaise446
- dizziness422
- asthenia418
- weight decreased409
- pain399
- product dose omission issue388
- injection site mass377
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 15 |
| 2009 | 4 |
| 2010 | 78 |
| 2011 | 67 |
| 2012 | 75 |
| 2013 | 41 |
| 2014 | 31 |
| 2015 | 26 |
| 2016 | 41 |
| 2017 | 1,043 |
| 2018 | 237 |
| 2019 | 277 |
| 2020 | 360 |
| 2021 | 973 |
| 2022 | 1,265 |
| 2023 | 1,154 |
| 2024 | 836 |
| 2025 | 913 |
| 2026 | 511 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,206 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site massSignal | 377 | 27.2 | 24.7 | 9,419 |
| abdominal painSignal | 573 | 6.5 | 6.0 | 2,700 |
| diarrhoeaSignal | 1,440 | 5.9 | 5.6 | 6,042 |
| injection site painSignal | 601 | 5.2 | 4.8 | 2,055 |
| off label useSignal | 1,514 | 4.6 | 4.4 | 4,408 |
| deathSignal | 1,278 | 3.9 | 3.7 | 2,900 |
| weight decreasedSignal | 409 | 3.9 | 3.5 | 881 |
| product dose omission issueSignal | 388 | 3.5 | 3.2 | 697 |
| fatigueSignal | 983 | 3.3 | 3.2 | 1,671 |
| astheniaSignal | 418 | 2.9 | 2.7 | 543 |
| malaiseSignal | 446 | 2.7 | 2.5 | 482 |
| nauseaSignal | 735 | 2.5 | 2.3 | 658 |
| dizzinessSignal | 422 | 2.2 | 2.0 | 295 |
| headacheSignal | 507 | 2.1 | 2.0 | 316 |
| pain | 399 | 1.7 | 1.6 | 123 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.